Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

    Carlos Gustavo Wambier, Sergio Vano-Galvan, John D. McCoy … Andy Goren
    Studysummary This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Androgenetic Alopecia in COVID-19: Compared to What? Journal of The American Academy of Dermatology · 2020
    2. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020
    3. Androgen Sensitivity Gateway to COVID-19 Disease Severity Drug Development Research · 2020
    4. Androgenetic Alopecia in Men Aged 40-69 Years: Prevalence and Risk Factors British Journal of Dermatology · 2003